Guy Goldberg, chief business officer of the Tel Aviv-based pharmaceutical company RedHill, which focuses on gastrointestinal diseases, discusses a groundbreaking new approach to Crohn’s that treats the underlying cause and could bring millions of sufferers into remission.





